Literature DB >> 15896317

Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization.

Nirbhai Singh1, Elizabeth Macnamara, Saadia Rashid, Jayakrishna Ambati, Christopher D Kontos, Eric Higgins, Balamurali K Ambati.   

Abstract

This study was designed to determine if soluble Tie2 (sTie2) expression inhibits and regresses corneal neovascularization, and if VEGF contributes to its effect. The corneas of BALB/c mice were scraped and the mice were injected with either an adenovirus expressing soluble Tie2 (Ad.sTie2) or an empty adenoviral vector. When injected at the inhibition timepoint (one day prior to corneal injury), the mean percentage of neovascularized corneal area two weeks later in Ad.sTie2-treated mice vs. controls was 56.37+/-9.15% vs. 85.79+/-3.55% (p=0.04). At the regression timepoint (4 weeks after corneal scrape), the mean area of corneal neovascularization in Ad.sTie2-treated mice was 42.89+/-4.74% vs. 75.01+/-3.22% in the control group (p=0.007). VEGF expression was significantly higher in Ad.sTie2-treated mice at the inhibition timepoint and there was no significant difference at the regression timepoint. These findings suggest that sTie2 inhibits and regresses corneal neovascularization in a VEGF-independent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896317     DOI: 10.1016/j.bbrc.2005.04.108

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 2.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

3.  A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

Authors:  G M Palmer; Z Tiran; Z Zhou; M E Capozzi; W Park; C Coletta; A Pyriochou; Y Kliger; O Levy; I Borukhov; M W Dewhirst; G Rotman; J S Penn; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Amniotic fluid angiopoietin-1, angiopoietin-2, and soluble receptor tunica interna endothelial cell kinase-2 levels and regulation in normal pregnancy and intraamniotic inflammation-induced preterm birth.

Authors:  Catalin S Buhimschi; Vineet Bhandari; Antonette T Dulay; Stephen Thung; Sonya S Abdel- Razeq; Victor Rosenberg; Christina S Han; Unzila A Ali; Eduardo Zambrano; Guomao Zhao; Edmund F Funai; Irina A Buhimschi
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

5.  High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Authors:  Issam Makhoul; Robert J Griffin; Eric Siegel; Jeannette Lee; Ishwori Dhakal; Vinay Raj; Azemat Jamshidi-Parsian; Suzanne Klimberg; Laura F Hutchins; Susan Kadlubar
Journal:  Am J Clin Oncol       Date:  2016-06       Impact factor: 2.339

6.  Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2.

Authors:  Francesca Gotsch; Roberto Romero; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Michael Dombrowski; Offer Erez; Nandor Gabor Than; Shali Mazaki-Tovi; Pooja Mittal; Jimmy Espinoza; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2008-06

7.  Evaluation of antiangiogenic and antiproliferative potential of the organic extract of green algae Chlorella pyrenoidosa.

Authors:  Mahender Kyadari; Tasneem Fatma; Rajvardhan Azad; Thirumurthy Velpandian
Journal:  Indian J Pharmacol       Date:  2013 Nov-Dec       Impact factor: 1.200

Review 8.  Endothelial Activation: The Ang/Tie Axis in Sepsis.

Authors:  Aleksandra Leligdowicz; Melissa Richard-Greenblatt; Julie Wright; Valerie M Crowley; Kevin C Kain
Journal:  Front Immunol       Date:  2018-04-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.